LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced the appointment of Jason Shallenberger to President of the Bone Growth Therapies business, and the realignment of its Spine business unit, effective March 1. A seasoned sales leader, Shallenberger previously served as Vice President of U.S.

德克萨斯州刘易斯维尔——（商业新闻短讯）——全球领先的脊柱和骨科公司Orthofix Medical Inc.（纳斯达克：OFIX）今天宣布任命杰森·沙伦伯格（JasonShallenberger）为骨生长疗法业务总裁，并重新调整其脊柱业务部门，自3月1日起生效。沙伦·伯格（Shallenberger）是一位经验丰富的销售领袖，曾任美国。

Sales and Marketing for the Orthofix Bone Growth Therapies business..

Orthofix骨生长疗法业务的销售和营销。。

Prior to this realignment, the Bone Growth Therapies business was managed under the leadership of the Company’s Spine business unit. Bone Growth Therapies and Spine will now be led by separate Presidents in alignment with the Company’s current business structures for Biologics and Enabling Technologies..

在此调整之前，骨生长疗法业务在公司脊柱业务部门的领导下进行管理。骨生长疗法和脊柱现在将由单独的总裁领导，与公司目前的生物制剂和使能技术业务结构保持一致。。

“Jason has led sales and marketing for this successful franchise for a number of years,” said Massimo Calafiore, President and Chief Executive Officer of Orthofix. “Under his guidance, the sales team has produced quarter-after-quarter of double-digit growth in 2023. I am confident he will do an amazing job as President and continue to contribute greatly to the success of Orthofix.”.

Orthofix总裁兼首席执行官马西莫·卡拉菲奥（MassimoCalafiore）表示：“杰森多年来一直领导着这一成功特许经营的销售和营销。”。“在他的指导下，销售团队在2023年实现了一季度又一季度的两位数增长。我相信他将作为总统做一份出色的工作，并继续为Orthofix的成功做出巨大贡献。”。

“Since 1986, Orthofix Bone Growth Therapy has helped promote the natural-bone healing process in patients,” said Shallenberger. “I am honored to continue my career with the company in this new role as we continue to innovate and bring new technologies to the market.”

Shallenberger说：“自1986年以来，Orthofix骨生长疗法有助于促进患者的自然骨愈合过程。”。“随着我们不断创新，将新技术推向市场，我很荣幸能在这个新的岗位上继续我的职业生涯。”

Shallenberger joined Orthofix in 2005 as a Territory Manager and quickly moved into the role of District Sales Manager before being promoted to the position of Regional Sales Director in 2008. He was promoted to Vice President of U.S. Sales and Marketing in 2011 and led his team to 30 consecutive quarters of year-over-year growth, outpacing annual market growth rates, and was given additional responsibilities for medical education in 2023.

沙伦·伯格（Shallenberger）于2005年加入Orthofix，担任地区经理，并迅速晋升为地区销售经理，然后于2008年晋升为区域销售总监。2011年，他被提升为美国销售和市场营销副总裁，带领团队连续30个季度同比增长，超过了年度市场增长率，并于2023年被赋予医学教育的额外职责。

Prior to joining Orthofix, Shallenberger worked as a specialty sales representative with Boehringer Ingelheim Pharmaceuticals. He is a graduate of the University of Nebraska..

在加入Orthofix之前，Shallenberger曾担任勃林格殷格翰制药公司的专业销售代表。他是内布拉斯加州大学的毕业生。。

About Bone Growth Therapies

关于骨骼生长疗法

Orthofix bone growth therapy devices provide a safe, noninvasive treatment that helps fractured bones and spinal fusions that have not healed or have difficulty healing. The devices stimulate the bone’s natural healing process by sending low-level pulses of electromagnetic energy or pulse ultrasound to the injury or nonunion site.

Orthofix骨生长治疗设备提供了一种安全、无创的治疗方法，可帮助骨折和脊柱融合，这些骨折尚未愈合或难以愈合。这些设备通过向受伤或骨不连部位发送低水平的电磁能量脉冲或脉冲超声波来刺激骨骼的自然愈合过程。

The market leader in the bone growth stimulation space, more than a million patients have been treated with Orthofix’s Pulsed Electromagnetic Field Stimulation (PEMF) devices. In 2022 Orthofix launched the AccelStim™ device with Low-Intensity Pulsed Ultrasound (LIPUS) technology, a nonsurgical treatment for indicated fresh fractures and for fractures that have not healed (nonunions).

作为骨生长刺激领域的市场领导者，Orthofix的脉冲电磁场刺激（PEMF）设备治疗了100多万名患者。2022年，Orthofix推出了具有低强度脉冲超声波（LIPUS）技术的AccelStim™设备，这是一种针对指示的新鲜骨折和未愈合骨折（骨不连）的非手术治疗方法。

This system is a part the portfolio of PEMF devices consisting of the SpinalStim™, CervicalStim™ and PhysioStim™ systems. To learn more about bone growth therapies visit bonegrowththerapy.com..

该系统是由SpinalStim™、CervicalStim™和PhysioStim™系统组成的PEMF设备组合的一部分。要了解有关骨生长疗法的更多信息，请访问bonegrowththerapy.com。。

Orthofix is a leading global spine and orthopedics company with a comprehensive portfolio of biologics, innovative spinal hardware, bone growth therapies, specialized orthopedic solutions, and a leading surgical navigation system. Its products are distributed in more than 60 countries worldwide.

Orthofix是一家全球领先的脊柱和骨科公司，拥有生物制剂、创新脊柱硬件、骨生长疗法、专业骨科解决方案和领先的外科导航系统的综合投资组合。其产品遍布全球60多个国家。

The Company is headquartered in Lewisville, Texas, where it conducts general business, product development, medical education and manufacturing, and has primary offices in Carlsbad, CA, with a focus on spine and biologics product innovation and surgeon education, and Verona, Italy, with an emphasis on product innovation, production, and medical education for orthopedics.

该公司总部位于德克萨斯州路易斯维尔（Lewisville），从事一般业务、产品开发、医学教育和制造，主要办事处位于加利福尼亚州卡尔斯巴德（Carlsbad），专注于脊柱和生物制品产品创新和外科医生教育，以及意大利维罗纳（Verona），重点是骨科产品创新、生产和医学教育。

The combined Company’s global R&D, commercial and manufacturing footprint also includes facilities and offices in Irvine, CA, Toronto, Canada, Sunnyvale, CA, Wayne, PA, Olive Branch, MS, Maidenhead, UK, Munich, Germany, Paris, France and Sao Paulo, Brazil..

合并后公司的全球研发、商业和制造足迹还包括位于加利福尼亚州欧文市、加拿大多伦多市、加利福尼亚州桑尼维尔市、宾夕法尼亚州韦恩市、橄榄枝市、MS、梅登黑德、英国、慕尼黑、德国、巴黎、法国和巴西圣保罗的设施和办事处。。

Forward-Looking Statements

前瞻性声明

This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “intends,” “predicts,” “potential,” “continue” or other comparable terminology.

本新闻稿可能包括经修订的《1934年证券交易法》第21E节和经修订的《1933年证券法》第27A节所指的前瞻性声明。在某些情况下，您可以通过术语来识别前瞻性陈述，例如“可能”、“将”、“应该”、“预期”、“计划”、“预期”、“相信”、“估计”、“项目”、“打算”、“预测”、“潜力”、“继续”或其他类似术语。

Orthofix cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Each forward-looking statement contained in this news release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement.

Orthofix提醒您，本新闻稿中不描述历史事实的陈述是基于公司当前预期和假设的前瞻性陈述。本新闻稿中包含的每一项前瞻性声明都存在风险和不确定性，这些风险和不确定性可能导致实际结果与该声明中明示或暗示的结果产生重大差异。

Applicable risks and uncertainties include, among others: the ability of newly launched products to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; and the risks identified under the heading “Risk Factors” in Orthofix Medical Inc.’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which was filed with the Securities and Exchange Commission (SEC) on March 6, 2023.

适用的风险和不确定性包括：新推出的产品能够按照设计和预期执行，并满足外科医生和患者的需求，包括由于缺乏强有力的临床验证；以及Orthofix Medical Inc.截至2022年12月31日财年的10-K表年度报告中“风险因素”标题下确定的风险，该报告于2023年3月6日提交给美国证券交易委员会（SEC）。

The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Orthofix does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law..

公司向证券交易委员会提交的公开文件可在www.sec.gov上查阅。请注意不要过度依赖前瞻性声明，因为前瞻性声明仅在发布之日起生效。Orthofix不打算修改或更新本新闻稿中规定的任何前瞻性声明，以反映本新闻稿日期后发生的事件或情况，法律可能要求的除外。。